XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2021
Revenue Recognition [Abstract]  
Revenue Recognition REVENUE RECOGNITION
Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2020.
We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.
Net Sales by Product Line
Three Months
20212020
Orthopaedics:
Knees$412 $432 
Hips309 316 
Trauma and Extremities640 392 
Other123 82 
$1,484 $1,222 
MedSurg:
Instruments$469 $513 
Endoscopy469 455 
Medical622 587 
Sustainability61 67 
$1,621 $1,622 
Neurotechnology and Spine:
Neurotechnology$570 $483 
Spine278 261 
$848 $744 
Total$3,953 $3,588 
Net Sales by Geography
Three Months 2021Three Months 2020
United StatesInternationalUnited StatesInternational
Orthopaedics:
Knees$294 $118 $322 $110 
Hips186 123 201 115 
Trauma and Extremities440 200 260 132 
Other94 29 69 13 
$1,014 $470 $852 $370 
MedSurg:
Instruments$355 $114 $410 $103 
Endoscopy354 115 364 91 
Medical473 149 454 133 
Sustainability60 1 66 1 
$1,242 $379 $1,294 $328 
Neurotechnology and Spine:
Neurotechnology$335 $235 $301 $182 
Spine193 85 196 65 
$528 $320 $497 $247 
Total$2,784 $1,169 $2,643 $945 
Contract Assets and Liabilities
On March 31, 2021 and December 31, 2020 contract assets recorded in our Consolidated Balance Sheets were not significant.
Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $444 and $416 on March 31, 2021 and December 31, 2020.